• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 3. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 4. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazines Phenothiazines

Recent Advances in the Study of 3,7-Dimethoxy-10H-Phenothiazine (CAS: 1730-43-4) and Its Applications in Chemical Biology and Medicine

3,7-Dimethoxy-10H-phenothiazine (CAS: 1730-43-4) is a derivative of phenothiazine, a heterocyclic compound that has garnered significant attention in chemical biology and pharmaceutical research due to its unique structural and electronic properties. Recent studies have explored its potential applications in drug development, photodynamic therapy, and as a building block for advanced materials. This research brief synthesizes the latest findings on this compound, highlighting its mechanisms of action, synthesis methods, and therapeutic potential.

One of the most promising areas of research involves the use of 3,7-dimethoxy-10H-phenothiazine as a photosensitizer in photodynamic therapy (PDT). A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits strong absorption in the visible light spectrum, making it an efficient generator of reactive oxygen species (ROS) upon irradiation. The study further revealed that 3,7-dimethoxy-10H-phenothiazine can selectively target cancer cells, inducing apoptosis with minimal damage to surrounding healthy tissues. These findings suggest its potential as a next-generation PDT agent for treating solid tumors.

In addition to its therapeutic applications, recent research has focused on the synthesis and modification of 3,7-dimethoxy-10H-phenothiazine to enhance its pharmacological properties. A 2024 paper in Organic & Biomolecular Chemistry reported a novel, high-yield synthesis route using palladium-catalyzed C-H activation, which significantly reduces the production of toxic byproducts compared to traditional methods. This advancement is particularly relevant for scaling up production while adhering to green chemistry principles.

The compound's unique electronic structure has also attracted attention in materials science. Researchers at MIT recently incorporated 3,7-dimethoxy-10H-phenothiazine into organic semiconductors, achieving record-high charge carrier mobility in thin-film transistors. This breakthrough, published in Advanced Materials, opens new possibilities for flexible electronics and bioelectronic interfaces.

Despite these advances, challenges remain in the clinical translation of 3,7-dimethoxy-10H-phenothiazine-based therapies. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability and rapid clearance in vivo. Current research efforts are focused on developing prodrug formulations and nanoparticle delivery systems to overcome these limitations. Preliminary results from animal models show promise, with improved tumor accumulation and reduced systemic toxicity.

In conclusion, 3,7-dimethoxy-10H-phenothiazine (CAS: 1730-43-4) represents a versatile scaffold with applications spanning medicine, materials science, and chemical biology. The compound's photophysical properties, combined with recent synthetic advances, position it as a valuable tool for both therapeutic development and fundamental research. Future studies should prioritize structure-activity relationship investigations and clinical translation efforts to fully realize its potential.

• 1771-18-2(2-Methoxy Phenothiazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)